TY - JOUR
T1 - Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein
AU - Kanety, Hannah
AU - Silbergeld, Aviva
AU - Klinger, Beatrice
AU - Karasik, Avraham
AU - Baxter, Robert C.
AU - Laron, Zvi
PY - 1997/12
Y1 - 1997/12
N2 - A minority of patients with Laron syndrome have normal serum GH binding protein (GHBP), indicating that the defect is elsewhere than in the extracellular domain of the GH receptor. We have evaluated the effect of long-term IGF-I treatment on serum IGF-binding protein (IGFBP)-3 and the acid-labile subunit (ALS) in three siblings with Laron syndrome caused by a GH post-receptor defect and with normal GHBP. The children (a boy aged 3 years, a girl aged 4 years and a boy aged 10 years) were treated by daily s.c. injection of IGF-I in a dose of 150 μg/kg. IGFBP-3 was measured by RIA and Western ligand blotting, ALS by RIA. Basal values of IGFBP-3 and ALS were low. During IGF-I treatment, the IGFBP-3 concentrations in the girl gradually increased, whereas in the boys there was a 60% decrease during the first week, followed by gradual increase towards baseline. The ALS concentrations followed a similar pattern. We conclude that IGF-I treatment induces an initial suppression and then an increase in the IGFBP-3 and ALS concentrations; confirming data from animal experiments that IGFBP-3 synthesis is not solely under GH control. The differences in responsiveness between the female and male siblings may reflect genetic differences, or lower circulating concentrations of IGF-I in the boys compared with the girl.
AB - A minority of patients with Laron syndrome have normal serum GH binding protein (GHBP), indicating that the defect is elsewhere than in the extracellular domain of the GH receptor. We have evaluated the effect of long-term IGF-I treatment on serum IGF-binding protein (IGFBP)-3 and the acid-labile subunit (ALS) in three siblings with Laron syndrome caused by a GH post-receptor defect and with normal GHBP. The children (a boy aged 3 years, a girl aged 4 years and a boy aged 10 years) were treated by daily s.c. injection of IGF-I in a dose of 150 μg/kg. IGFBP-3 was measured by RIA and Western ligand blotting, ALS by RIA. Basal values of IGFBP-3 and ALS were low. During IGF-I treatment, the IGFBP-3 concentrations in the girl gradually increased, whereas in the boys there was a 60% decrease during the first week, followed by gradual increase towards baseline. The ALS concentrations followed a similar pattern. We conclude that IGF-I treatment induces an initial suppression and then an increase in the IGFBP-3 and ALS concentrations; confirming data from animal experiments that IGFBP-3 synthesis is not solely under GH control. The differences in responsiveness between the female and male siblings may reflect genetic differences, or lower circulating concentrations of IGF-I in the boys compared with the girl.
UR - http://www.scopus.com/inward/record.url?scp=0031438098&partnerID=8YFLogxK
U2 - 10.1530/eje.0.1370626
DO - 10.1530/eje.0.1370626
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9437227
AN - SCOPUS:0031438098
SN - 0804-4643
VL - 137
SP - 626
EP - 630
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 6
ER -